Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
Pursuing Platform, Pipeline, Modality Diversity
Executive Summary
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.